Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 43Neoplasms 13Neoplasm Metastasis 8Sarcoma 7Carcinoma, Non-Small-Cell Lung 5Triple Negative Breast Neoplasms 4Sarcoma, Ewing 2Rhabdomyosarcoma 2Prostatic Neoplasms 2Liposarcoma 2Leiomyosarcoma 2Inflammatory Breast Neoplasms 2Carcinoma 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasm, Residual 1Metastatic Urothelial Cell Cancer 1Lymphoma 1Lung Neoplasms 1Ketosis 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Hemangioendothelioma, Epithelioid 1

Interventions

eribulin 1Trastuzumab 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × HER-2 Positive Breast Cancer × eribulin × Clear all
NCT01388647 2015-08-28

Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer

Vector Oncology

Phase 1/2 Terminated
12 enrolled 12 charts
Breast

HER-2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡